Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Breast Neoplasms 401Colorectal Neoplasms 317Rectal Neoplasms 235Stomach Neoplasms 209Pancreatic Neoplasms 137Neoplasm Metastasis 123Colonic Neoplasms 94Neoplasms 86Triple Negative Breast Neoplasms 64Esophageal Neoplasms 57Biliary Tract Neoplasms 39Nasopharyngeal Carcinoma 37Cholangiocarcinoma 31Adenocarcinoma 31Carcinoma, Hepatocellular 30Gallbladder Neoplasms 29Carcinoma, Non-Small-Cell Lung 21Bile Duct Neoplasms 21Locally Advanced Rectal Cancer 20Adenocarcinoma Of Esophagus 20Squamous Cell Carcinoma of Head and Neck 19Brain Neoplasms 19Gastrointestinal Neoplasms 18Parkinson Disease 4, Autosomal Dominant Lewy Body 17Liver Neoplasms 17Head and Neck Neoplasms 17Esophageal Squamous Cell Carcinoma 17Colorectal Cancer Metastatic 15Ovarian Neoplasms 14Breast Neoplasms, Male 14

Interventions

Gemcitabine 15130-nm albumin-bound paclitaxel 10Albumin-Bound Paclitaxel 7Oxaliplatin 5Paclitaxel 4Leucovorin 4Fluorouracil 4Carboplatin 4Cisplatin 3Cetuximab 3Bevacizumab 3pembrolizumab 2napabucasin 2Pemetrexed 2PEGPH20 2MK-4721 2Irinotecan 2tremelimumab 1selinexor 1relacorilant 1ponatinib 1neratinib 1irinotecan sucrosofate 1folfirinox 1ensituximab 1durvalumab 1contrast agent BR1 1cobimetinib 1ceritinib 1cc-486 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Pancreatic Ductal × Capecitabine × Clear all
NCT02243007 2017-05-16

Phase II Study of Preoperative FOLFIRINOX Versus Gemcitabine/Nab-Paclitaxel in Patients With Resectable Pancreatic Cancer

Massachusetts General Hospital

Phase 2 Terminated
7 enrolled 8 charts
Gastrointestinal

Carcinoma, Pancreatic Ductal

Data powered by HemOnc (CC BY 4.0) Colophon âš¡